2020 American Heart Association Scientific Sessions*

Omecamtiv mecarbil associated with decreased risk of a composite of heart failure events and cardiovascular death but not individual components of this endpoint.

In patients with iron deficiency, FCM reduced risk of HFH with no apparent effect on risk of CV death.

High-dose trivalent influenza vaccine was comparable to standard-dose quadrivalent vaccine regarding deaths or cardiopulmonary hospitalizations.

Risk of CV death or hospitalization for HF was highest in patients with hospitalization for HF within 3 months prior to study.